Clinical Takeaway
In a controlled crossover trial of healthy males, neither a low (30 mg) nor a high (700 mg) single dose of CBD produced measurable changes in cortical excitability compared to placebo. This suggests CBD may not have meaningful direct anti-epileptic effects on its own, and its clinical benefit in seizure disorders like Dravet syndrome likely depends on its pharmacokinetic interaction with clobazam rather than intrinsic brain activity modulation. Patients and clinicians should understand that CBD’s seizure-reducing effects in these conditions are probably not a standalone action on the brain.
#10 Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.
Citation: Gorbenko Andriy A et al.. Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.. Clinical pharmacology and therapeutics. 2026. PMID: 40836528.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This study clarifies the mechanism of CBD’s clinical efficacy by demonstrating that its anti-seizure effects in approved indications likely derive from pharmacokinetic interactions with concurrent ASMs rather than direct cortical effects, which has important implications for polypharmacy considerations and patient counseling. Understanding that CBD lacks direct modulation of cortical excitability helps clinicians better predict efficacy and adverse effects when combining CBD with other ASMs, particularly clobazam. These findings support more targeted use of CBD in seizure management and inform the design of future trials examining optimal drug combinations for refractory epilepsy.
Abstract: Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox-Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti-seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti-epileptic and sedative properties of CBD. A randomized, double-blind, placebo-controlled, 3-way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed-effects model. CBD did not have significant effects on single pulse and paired pulse TMS-EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS-EEG at 3 hours post-dose for 30 mg CBD, and at 3 and 5 hours post-dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti-epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.
🧠 This well-designed crossover trial challenges a common assumption about cannabidiol’s mechanism by demonstrating that CBD does not directly suppress cortical excitability in the way traditional antiepileptic drugs do, suggesting its clinical efficacy in seizure disorders may rely primarily on pharmacokinetic interactions with concurrent medications like clobazam rather than intrinsic neuronal effects. While this finding is mechanistically important, clinicians should recognize that lack of direct cortical effects does not diminish CBD’s demonstrated clinical utility in approved indications, particularly in Dravet and Lennox-Gastaut syndromes where drug-drug interactions may be the operative therapeutic pathway. The study’s limitation to a single timepoint and potentially healthy or non-seizure-prone participants warrants caution in fully generalizing these findings to the complex, chronic seizure populations we actually treat. Practically speaking, this research reinforces the importance of understanding that CBD’s value in our seizure management toolkit may depend critically on which concurrent medications a patient is taking,